Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L, Lafky JM, Smith E, Pachman D, Staff N, Ma C, Loprinzi CL, Costello BA. Albany C, et al. Support Care Cancer. 2021 Nov;29(11):7129-7130. doi: 10.1007/s00520-021-06523-z. Support Care Cancer. 2021. PMID: 34480623 No abstract available.
Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
Le-Rademacher J, Kanwar R, Seisler D, Pachman DR, Qin R, Abyzov A, Ruddy KJ, Banck MS, Lavoie Smith EM, Dorsey SG, Aaronson NK, Sloan J, Loprinzi CL, Beutler AS. Le-Rademacher J, et al. Support Care Cancer. 2017 Nov;25(11):3537-3544. doi: 10.1007/s00520-017-3780-y. Epub 2017 Jun 20. Support Care Cancer. 2017. PMID: 28634656 Free PMC article.
Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.
Smith EML, Zanville N, Kanzawa-Lee G, Donohoe C, Bridges C, Loprinzi C, Le-Rademacher J, Yang JJ. Smith EML, et al. Support Care Cancer. 2019 Jul;27(7):2599-2608. doi: 10.1007/s00520-018-4553-y. Epub 2018 Nov 20. Support Care Cancer. 2019. PMID: 30460399 Free PMC article.
Patient factors associated with discrepancies between patient-reported and clinician-documented peripheral neuropathy in women with breast cancer receiving paclitaxel: A pilot study.
Salgado TM, Liu J, Reed HL, Quinn CS, Syverson JG, Le-Rademacher J, Lopez CL, Beutler AS, Loprinzi CL, Vangipuram K, Smith EML, Henry NL, Farris KB, Hertz DL. Salgado TM, et al. Breast. 2020 Jun;51:21-28. doi: 10.1016/j.breast.2020.02.011. Epub 2020 Mar 3. Breast. 2020. PMID: 32193049 Free PMC article.
A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102.
Cathcart-Rake E, Novotny P, Leon-Ferre R, Le-Rademacher J, Storrick EM, Adjei AA, Terstriep S, Glaser R, Giuliano A, Mitchell WR, Page S, Austin C, Deming RL, Ferreira MA, Lafky JM, Birrell SN, Loprinzi CL. Cathcart-Rake E, et al. Support Care Cancer. 2021 Jan;29(1):387-396. doi: 10.1007/s00520-020-05473-2. Epub 2020 May 6. Support Care Cancer. 2021. PMID: 32372176 Free PMC article. Clinical Trial.
Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C, Dockter T, Wolfe E, Le-Rademacher J, Wagner-Johnston N, Einhorn L, Lafky JM, Smith E, Pachman D, Staff N, Ma C, Loprinzi CL, Costello BA. Albany C, et al. Support Care Cancer. 2021 Feb;29(2):833-840. doi: 10.1007/s00520-020-05543-5. Epub 2020 Jun 4. Support Care Cancer. 2021. PMID: 32500206 Free PMC article.
144 results